Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | ICG reduces leak rates in left-sided colorectal anastomosis

Zoe Garoufalia, MD, PhD, Hygeia Hospital, Athens, Greece, highlights the evolution of evidence regarding indocyanine green (ICG) fluorescence in colorectal surgery, noting that inconsistent study populations and outcome metrics across multiple randomized controlled trials previously limited clinical consensus. A 2026 systematic review and meta-analysis clarified ICG’s efficacy in reducing anastomotic leak rates in left-sided colorectal resections, while evidence for right-sided procedures remains inconclusive. An ongoing multicenter observational trial has been designed to establish standardized protocols and clinically meaningful thresholds, with the goal of developing an artificial intelligence-based algorithm to objectively quantify fluorescence intensity and address the persistent clinical question of determining adequate tissue perfusion. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I was tormented so far because we have at least nine randomized controlled trials that, because they are not designed with not always the proper question in mind, but because they have this inconsistent study populations and the metrics that they use are different and their outcomes are different, you come across those inconsistent results that give room to interpretation and room to not use or use ICG...

I was tormented so far because we have at least nine randomized controlled trials that, because they are not designed with not always the proper question in mind, but because they have this inconsistent study populations and the metrics that they use are different and their outcomes are different, you come across those inconsistent results that give room to interpretation and room to not use or use ICG. ICG, let’s say. But in 2026, there was a groundbreaking systematic review and meta-analysis public in the Lancet, gastroenterology and hepatology, by the group of Professor Ronan Cahill that actually put a stop to this. They meta-analyzed these nine randomized controlled trials and the evidence now is CLEAR. ICG—the use of ICG does reduce the leak rates in left-sided colorectal intersection. The jury is still out in the right-sided ones. I invite everyone to read that systematic review and meta-analysis and, of course, take their interpretation in the RCTs as well. launching, actually, a trial, a multi-center observational trial, trying to get standardized protocols, reliable metrics, and clinically significant thresholds. So through that, we can real-time CREATE an algorithm, maybe using AI, that actually can quantify the green that we see in front of our eyes. Because the question that constantly is out there is, how much green is green enough?

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.